Metadon (Methadone Hydrochloride)

Methadone is used in the management of opioid‑related conditions and chronic pain.

• Opioid dependence: stabilizes patients on opioid substitution therapy to reduce illicit use and withdrawal symptoms.
• Chronic pain: provides long‑acting analgesia for severe, persistent pain when other opioids are insufficient.
• Opioid withdrawal management: facilitates gradual tapering during detoxification programs to minimize withdrawal discomfort.

• Methadone acts as a full agonist at the µ‑opioid receptor, binding with high affinity and producing analgesic and euphoric effects while suppressing withdrawal. It also blocks the reuptake of serotonin and norepinephrine, contributing to its analgesic profile. The long half‑life provides sustained receptor activation, allowing once‑daily dosing in maintenance therapy.

Methadone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Constipation: reduced bowel movements.
• Drowsiness: increased sleepiness or fatigue.
• Sweating: excessive perspiration.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing, potentially life‑threatening.
• Cardiac arrhythmia: QT interval prolongation leading to irregular heart rhythm.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing methadone, clinicians should observe several safety considerations to minimize risks.

• Assess patient history: evaluate prior opioid use, respiratory disorders, and cardiac conditions.
• Monitor dosing closely: adjust based on response and avoid rapid dose escalations.
• Screen for drug interactions: review concomitant medications that affect CYP enzymes.
• Educate patients: advise on signs of overdose and the importance of adherence.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Methadone interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce methadone plasma levels, risking withdrawal.

Moderate Interactions (Monitor Closely)

• CYP2B6 inhibitors (e.g., fluoxetine, sertraline): may increase methadone concentrations, requiring dose adjustment.
• QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): can enhance risk of cardiac arrhythmias.
• Alcohol: additive sedative effects that may exacerbate respiratory depression.